BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
6.61
-0.20 (-2.94%)
At close: Oct 2, 2026, 4:00 PM EDT
6.74
+0.13 (1.97%)
After-hours: Oct 2, 2026, 7:30 PM EDT
BioAge Labs Revenue
BioAge Labs had revenue of $2.45M in the quarter ending June 30, 2026, with 1.62% growth. This brings the company's revenue in the last twelve months to $10.36M, up 168.06% year-over-year. In the year 2025, BioAge Labs had annual revenue of $9.00M.
Revenue (ttm)
$10.36M
Revenue Growth
+168.06%
P/S Ratio
29.30
Revenue / Employee
$167,016
Employees
62
Market Cap
303.38M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
BIOA News
- 7 days ago - BioAge Labs to Present at Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - BioAge Labs Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 21 days ago - BioAge Labs Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 23 days ago - BioAge Labs Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 24 days ago - BioAge Labs doses first patient in QUELL-DME study - TheFly
- 24 days ago - BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema - GlobeNewsWire
- 1 month ago - BioAge Labs price target lowered to $20 from $23 at Morgan Stanley - TheFly
- 1 month ago - BioAge Labs price target lowered to $21 from $52 at Citi - TheFly